Indaptus Therapeutics (INDP) Free Cash Flow (2020 - 2026)
Indaptus Therapeutics (INDP) posted quarterly Free Cash Flow of -$7.0 million for Q1 2026, down 38.89% year-over-year from -$11.5 million in Q1 2025, and down 173.04% quarter-over-quarter from -$2.6 million in Q3 2025.
Indaptus Therapeutics (INDP) Free Cash Flow (2020 - 2026) Analysis & Trends
Indaptus Therapeutics' Free Cash Flow history runs 7 years deep, the most recent figure standing at -$7.0 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 38.89% year-over-year to -$7.0 million; the TTM figure through Mar 2026 stood at -$13.6 million (down 1.2% YoY), while the FY2024 annual figure was -$12.3 million, up 8.07% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$7.0 million, down from -$2.6 million in the prior quarter.
- The five-year high for Free Cash Flow was -$2.1 million in Q2 2023, with the low at -$7.0 million in Q1 2026.
- The 5-year median for Free Cash Flow is -$3.3 million (2022), against an average of -$3.6 million.
- Peak annual rise in Free Cash Flow reached 37.54% in 2022, while the deepest fall reached 277.18% in 2022.
- Indaptus Therapeutics' Free Cash Flow stood at -$2.2 million in 2022, then decreased by 17.69% to -$2.6 million in 2023, then sank by 30.51% to -$3.4 million in 2024, then advanced by 24.39% to -$2.6 million in 2025, then slumped by 173.04% to -$7.0 million in 2026.
- Business Quant data shows INDP's Free Cash Flow at -$7.0 million in Q1 2026, -$2.6 million in Q3 2025, and -$4.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Indaptus Therapeutics | 146.91 Mn | 135.35 Mn | - | -1.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.93 Mn |
| Jun 30, 2026 | -1.93 Mn |
| Mar 31, 2026 | -7.01 Mn |
| Mar 31, 2026 | -7.01 Mn |
| Sep 30, 2025 | -2.57 Mn |
| Sep 30, 2025 | -2.57 Mn |
| Jun 30, 2025 | -4.02 Mn |
| Jun 30, 2025 | -4.02 Mn |
| Mar 31, 2025 | -5.05 Mn |
| Mar 31, 2025 | -5.05 Mn |
| Dec 31, 2024 | -3.40 Mn |
| Dec 31, 2024 | -3.40 Mn |
| Sep 30, 2024 | -2.51 Mn |
| Sep 30, 2024 | -2.51 Mn |
| Jun 30, 2024 | -2.48 Mn |
| Jun 30, 2024 | -2.48 Mn |
| Mar 31, 2024 | -3.94 Mn |
| Mar 31, 2024 | -3.94 Mn |
| Dec 31, 2023 | -2.60 Mn |
| Dec 31, 2023 | -2.60 Mn |